At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
Fulvestrant +1 moredrug
Likely dose
Fulvestrant 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Multicentre Trial to Compare the Anti-tumour Effects and Tolerability of a 500 mg Dose of Faslodex (Fulvestrant) Plus Arimidex (Anastrozole) With a 500 mg Dose of Faslodex(Fulvestrant) Alone and With Arimidex(Anastrozole) Alone, in Postmenopausal Women Prior to Surgery for Primary Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Fulvestrant and Anastrazole for Breast Cancer. Completed, enrolled 120 participants across 1 site.
Detailed Summary
To compare the anti-tumour effects as measured by changes in various biomarkers, of a combination of Faslodex and Arimidex with Faslodex alone and Arimidex alone in postmenopausal women patients with primary breast cancer who are awaiting curative-intent surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2004
First PostedNov 2005
Primary CompletionOct 2008
TodayJul 2026
First PostedNov 29, 2005
Enrollment StartApr 1, 2004
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 20.6 years ago
Interventions
Fulvestrantdrug
500 mg intramuscular injection
Anastrazoledrug
oral tablet